Mayo Clinic, Rochester, MN
Joshua Pritchett , Jonas Paludo , Qian Shi , Nandita Khera , Zachary Yetmar , John W. Wilson , Rozalina McCoy , Angela Leuenberger , Sarah Phillips , Kristina Pearson , Samantha McColley , Robert Haemmerle , Lindsey R. Sangaralingham , Alexander J. Ryu , David Phelan , Naseema Gangat , Julian R. Molina , Jon Charles Tilburt , Bijan J. Borah , Tufia C. Haddad
Background: Ambulatory management of select patients with febrile neutropenia (FN) may substantially decrease patients’ burden of illness and improve their quality of life, and is recommended by American Society of Clinical Oncology (ASCO) guidelines. However, in the United States, inpatient management remains the universal standard. We hereby report the health care utilization associated with the DEFeNDR remote patient monitoring (RPM) program, which leverages technology and virtual centralized nurse monitoring to facilitate ambulatory management of FN as an alternative to hospital-based care. Methods: Adult patients with cancer hospitalized with FN were assessed daily for eligibility to participate in the DEFeNDR program. Eligibility criteria included MASCC score >21 (per ASCO guidelines), and clinical judgment of the attending provider. Patients receiving cellular therapy (CAR-T, BMT) in the prior 100 days were excluded. Eligible patients agreeing to participate in the 30-day program were provided a kit containing cellular-enabled, pre-connected devices to facilitate monitoring, including twice-daily vital signs and electronic symptom questionnaires. Data were EHR-integrated in real-time and embedded decision trees facilitated alerts for adverse trends. RPM nurses responded to alerts and escalated care as indicated by pre-specified care pathways. Program assessment was performed at 20 weeks after full implementation. The primary outcome was the mean proportion of evaluable days spent inpatient (mPEDI) within 30 days of eligibility compared between those who participated in the program vs. those who declined. Results: 35 patients were offered participation in the DEFeNDR program. Of these, 17 participated and 18 declined. Baseline characteristics are provided. Participating patients experienced mPEDI of 6.9% (Standard Error [SE], 3.7%), compared with 17.7% (SE, 3.6%) for patients who declined participation. Due to small sample size, this difference (10.8%) did not reach statistical significance (Wilcoxon Rank Sums p-value, 0.15). 30-day mortality did not differ between groups. Mean inpatient days were also lower for patients participating in the program. Additionally, when readmitted, patients participating in RPM experienced a trend toward shorter length of stay and lower rates of intensive care unit utilization. Conclusions: A trend towards decreased burden of inpatient care is evident among patients participating in the DEFeNDR program. Further studies are warranted to assess comparative effectiveness of this model vs usual care.
Participated | Declined | |
---|---|---|
n | 17 | 18 |
Median Age, years (range) | 60 (24-76) | 59 (25-79) |
% Female | 41% | 50% |
mPEDI (30d) | 6.90% | 17.70% |
Mean inpatient days (30d) | 1.9 | 4.7 |
All-cause mortality (30d) | 1 | 1 |
Readmissions (30d): mean inpatient days | 3 | 6.9 |
Readmissions (30d): ICU utilization rate | 17% | 38% |
Readmissions (30d): mean ICU days | 1.0 | 2.0 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Quality Care Symposium
First Author: Joshua Pritchett
2024 ASCO Annual Meeting
First Author: Youjin Oh
2023 ASCO Genitourinary Cancers Symposium
First Author: Giulia Kodja Zanetta
2024 ASCO Annual Meeting
First Author: Arun Kumar